DIVISION OF CORPORATION FINANCE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

Mail Stop 4645

January 26, 2017

Mark L. Baum Chief Executive Officer Imprimis Pharmaceuticals, Inc. 12264 El Camino Real, Suite 350 San Diego, California 92130

Re: Imprimis Pharmaceuticals, Inc.

Registration Statement on Form S-3

Filed January 23, 2017 File No. 333-215672

Dear Mr. Baum:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Chris Edwards at (202) 551-6761 with any questions.

Sincerely,

/s/ Mary Beth Breslin for

Suzanne Hayes Assistant Director Office of Healthcare and Insurance

cc: Andrew D. Hudders, Esq.